Why Amgen Inc. (AMGN) stock moved
Amgen Inc. (AMGN) shares rose 1.1% to $466.01 as of October 31, 2026, a modest gain from the prior close of $460.73. BestStocks flagged the session as a major change for AMGN. The move is tied to company news. Below, we break down what changed for AMGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Amgen scheduled third quarter 2026 earnings release for November 3, 2026, after market close. Q3 results will reveal revenue, profit, drug pipeline progress, and updated 2026 guidance affecting stock valuation.
What it means for Amgen Inc. investors
For Amgen Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 1.1% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Because peers moved similarly, the shift looks more macro- or sector-driven than a change in AMGN's fundamentals. Wall Street's consensus price target sits at $403.79, implying -13.4% downside from $466.01. Over the past 90 days analysts logged 0 upgrades and 2 downgrades. BestStocks rates the overall signal quality low (46/100). With earnings roughly 3 days out, the next report is the most likely near-term test of the move.
AMGN price reaction
AMGN last traded at $466.01, up $5.28 (+1.15%) from the previous close of $460.73. The session traded on 1.2× average volume (normal), so participation was unremarkable. Its healthcare peer group moved a median +1.4% over the same stretch, leaving AMGN essentially in line with peers.
Bullish and bearish analyst opinions on Amgen Inc. (AMGN)
The consensus analyst price target on Amgen Inc. (AMGN) is $403.79, 13.4% below the recent $466.01. Over the past 90 days analysts logged 0 upgrades, 35 maintains, and 2 downgrades. Here is how the bullish and bearish cases on AMGN line up.
The bullish case
- The Street's most bullish target is $500.00 (+7.3%).
- Positive 1.1% session move.
- Positive price momentum.
The bearish case
- The consensus analyst price target of $403.79 sits 13.4% below the recent $466.01, so the average target sees limited room to run.
- The most bearish analyst target is $230.00 (-50.6%).
- 2 analyst downgrades in the past 90 days, most recently HSBC to Hold (2026-09-10).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Oct 31, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for AMGN
Frequently asked questions about AMGN
Why did Amgen Inc. (AMGN) stock move?
AMGN rose 1.1% to $466.01. The move is associated with company news and looks like a sector-wide move.
How much did AMGN stock rise?
AMGN gained 1.15% ($5.28) versus the prior close of $460.73, last trading at $466.01 on 1.2× average volume.
When is Amgen Inc.'s next earnings date?
AMGN's next earnings report is estimated for 2026-11-03 — about 3 days away.
What is the analyst price target for AMGN?
The consensus analyst price target for AMGN is $403.79, about 13.4% below the current $466.01. Over the past 90 days, analysts recorded 0 upgrades, 35 maintains, and 2 downgrades.
Is the AMGN move company-specific or sector-wide?
BestStocks classifies it as a sector-wide move: the peer group moved a median +1.4% against AMGN's +1.1%. AMGN ranks top 5 of 7 peers.
How BestStocks tracks AMGN
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for AMGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of October 31, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
